Valneva SE – LSE:0OB3.L

Valneva SE stock price today

EUR 23.12
+21
+990.57%
Financial Health
0
1
2
3
4
5
6
7
8
9

Valneva SE stock price monthly change

-38.37%
month

Valneva SE stock price quarterly change

-38.37%
quarter

Valneva SE stock price yearly change

-55.83%
year

Valneva SE key metrics

Market Cap
 309.52M
Enterprise value
 N/A
P/E
 N/A
EV/Sales
 N/A
EV/EBITDA
 N/A
Price/Sales
 N/A
Price/Book
 N/A
PEG ratio
 N/A
EPS
 -0.18
Revenue
 152.95M
EBITDA
 -86.93M
Income
 -24.39M
Revenue Q/Q
 -2.25%
Revenue Y/Y
 -58.98%
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 -56.84%

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Valneva SE stock price history

Valneva SE stock forecast

Valneva SE financial statements

Profit Margin

Valneva SE (LSE:0OB3.L): Profit margin
Jun 2023 40.23M -16.91M -42.05%
Sep 2023 38.07M -34.22M -89.9%
Dec 2023 41.89M -32.15M -76.75%
Mar 2024 32.75M 58.90M 179.86%
0OB3.L income statement history

Valneva SE Financials Estimate

Valneva SE (LSE:0OB3.L): Analyst Estimates
2027 414.26M 70.00M 16.9%

  • Analysts Price target

  • Financials & Ratios estimates

Show more

Quarterly Earnings

Valneva SE (LSE:0OB3.L): Earnings per share (EPS)
2024-12-10 -0.12207 -0.05087
0OB3.L earnings history

Debt to Assets

Valneva SE (LSE:0OB3.L): Debt to assets
Jun 2023 542571000 351.86M 64.85%
Sep 2023 520539000 363.01M 69.74%
Dec 2023 469391000 341.14M 72.68%
Mar 2024 502829000 313.60M 62.37%
0OB3.L balance sheet history

Cash Flow

Valneva SE (LSE:0OB3.L): Cash Flow
Jun 2023 -41.10M -3.07M -5.66M
Sep 2023 -71.40M 2.36M 35.61M
Dec 2023 -69.22M -16.80M 40.74M
Mar 2024 -34.00M 86.44M -1.62M
0OB3.L cash flow history

Valneva SE alternative data

Valneva SE
Employees

Valneva SE (LSE:0OB3.L): Employee count
Aug 2023 719
Sep 2023 719
Oct 2023 700
Nov 2023 700
Dec 2023 719
Jan 2024 719
Feb 2024 719
Mar 2024 676
Apr 2024 676
May 2024 676
Jun 2024 676
Jul 2024 676

Valneva SE other data

Valneva SE
Patents

Patent
Application
Filling date: 19 May 2020 Issue date: 16 Jun 2022
Grant
Filling date: 20 Aug 2021 Issue date: 14 Jun 2022
Application
Filling date: 20 Aug 2021 Issue date: 20 Jan 2022
Application
Filling date: 22 Nov 2019 Issue date: 20 Jan 2022
Grant
Filling date: 4 Dec 2019 Issue date: 28 Dec 2021
Application
Filling date: 19 Sep 2018 Issue date: 21 Oct 2021
Application
Filling date: 15 Jul 2019 Issue date: 9 Sep 2021
Application
Filling date: 6 Apr 2020 Issue date: 26 Nov 2020
Application
Filling date: 11 Mar 2020 Issue date: 5 Nov 2020
Application
Filling date: 4 Dec 2019 Issue date: 25 Jun 2020
0OB3.L patents

Valneva SE
Executives

Insider Compensation
Mr. Thomas Lingelbach (1963) Chairman of the Management Board, Pres & Chief Executive Officer
 $652,940
Mr. David Lawrence (1963) Chief Financial Officer & Member of Management Board
 $466,180
Mr. Franck Grimaud (1967) Pres, Chief Bus. Officer & Member of Management Board
 $415,740
Mr. Frédéric Jacotot (1964) Gen. Counsel, Sec. & Member of Management Board
 $295,310
Ms. Janet Hoogstraate Chairman of the Management Board of Valneva Sweden AB
Mr. Christian Taucher Head of Global Medical Affairs
Mr. Gerald Strohmaier HR Officer
Dr. Juan-Carlos Jaramillo M.D. Chief Medical Officer & Member of the Management Board
Laetitia Bachelot-Fontaine Global Head of Investor Relations & Corporation Communications
Kerstin Westritschnig Head of Clinical Devel., Vice President and Senior Medical Officer

Frequently Asked Questions (FAQ)

  • What's the price of Valneva SE stock today?

    One share of Valneva SE stock can currently be purchased for approximately $23.12.

  • When is Valneva SE's next earnings date?

    Valneva SE is estimated to report earnings on Tuesday, 12 Aug 2025.

  • Does Valneva SE pay dividends?

    No, Valneva SE does not pay dividends.

  • How much money does Valneva SE make?

    Valneva SE has a market capitalization of 309.52M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 57.46% to 153.71M US dollars. Valneva SE made a loss 101.43M US dollars in net income (profit) last year or -$0.05 on an earnings per share basis.

  • What is Valneva SE's stock symbol?

    Valneva SE is traded on the LSE under the ticker symbol "0OB3.L".

  • What is Valneva SE's primary industry?

    Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.

  • How do i buy shares of Valneva SE?

    Shares of Valneva SE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Valneva SE's key executives?

    Valneva SE's management team includes the following people:

    • Mr. Thomas Lingelbach Chairman of the Management Board, Pres & Chief Executive Officer(age: 62, pay: $652,940)
    • Mr. David Lawrence Chief Financial Officer & Member of Management Board(age: 62, pay: $466,180)
    • Mr. Franck Grimaud Pres, Chief Bus. Officer & Member of Management Board(age: 58, pay: $415,740)
    • Mr. Frédéric Jacotot Gen. Counsel, Sec. & Member of Management Board(age: 61, pay: $295,310)
    • Ms. Janet Hoogstraate Chairman of the Management Board of Valneva Sweden AB
    • Mr. Christian Taucher Head of Global Medical Affairs
    • Mr. Gerald Strohmaier HR Officer
    • Dr. Juan-Carlos Jaramillo M.D. Chief Medical Officer & Member of the Management Board
    • Laetitia Bachelot-Fontaine Global Head of Investor Relations & Corporation Communications
    • Kerstin Westritschnig Head of Clinical Devel., Vice President and Senior Medical Officer

  • How many employees does Valneva SE have?

    As Jul 2024, Valneva SE employs 676 workers.

  • When Valneva SE went public?

    Valneva SE is publicly traded company for more then 14 years since IPO on 17 Feb 2011.

  • What is Valneva SE's official website?

    The official website for Valneva SE is valneva.com.

  • How can i contact Valneva SE?

    Valneva SE can be reached via phone at +33 2 28 07 37 10.

Valneva SE company profile:

Valneva SE

valneva.com
Exchange:

LSE

Full time employees:

676

Industry:

Medical - Pharmaceuticals

Sector:

Healthcare

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.

+33 2 28 07 37 10
6 rue Alain Bombard
Saint-Herblain, 44800

:
ISIN: FR0004056851
: